Outline Agenda
BELLAGIO CONFERENCE 2014

DAY ONE / WHAT IS OPEN SOURCE PHARMA? CONTEXT, DEFINITIONS, PRACTICE

9:00 am          Introduction
                         Jay Menon, Zakir Thomas, Matthew Todd, All                                                            

• Welcome
• Statement of purpose
• Roundtable:  Introductions and statements of wish from each participant
• Quotations: The magic of Bellagio

10:30 am        Setting the Scene: What Is Wrong in the Kingdom of Drug R&D?
                         Bernard Munos, Piero Olliaro

• Current needs and gaps (Munos)
• Whether and why the current system fails (Munos)
• Illustration: TB pipeline-current status and peculiarities of TB (Olliaro)

12:15 pm       The Alternatives:  What Is Being Tried?
                        Bernard Munos, Rob Don, Piero Olliaro, Manica Balasegaram, Melinda Richter, John McKew, Jörg Bentzien, Dimitrios Tzalis
                         Jay Menon, Sherwood Neiss

What are the existing alternative incentives and enabling mechanisms  - e.g., PDPs, and pharma spin offs and initiatives? What have they delivered? What are they promising to deliver? Are such initiatives solutions, or partial solutions?  What do they have planned on the horizon?

• Overview of alternatives (Munos)
• PDP experience (Don)
• Current Initiatives in TB Drug Discovery/Development (Olliaro)
• MSF Access Campaign experience + regimen focus (Balasegaram)
• The view from Janssen Labs, a Johnson & Johnson company (Richter)
• The view from NIH (McKew)
• Kaggle, gamification, and other crowdfunding experiments (Bentzien)
• The view from the European Lead Factory (Tzalis)
• Spur your imagination – Examples from other fields (Menon/Neiss)

1:00 pm          Lunch

2:15 pm          The Alternatives:  What Is Being Tried? - continued                         
                        Bernard Munos, Rob Don, Piero Olliaro, Manica Balasegaram, Melinda Richter, John McKew, Jörg Bentzien, Dimitrios Tzalis
                         Jay Menon, Sherwood Neiss

What are the existing alternative incentives and enabling mechanisms  - e.g., PDPs, and pharma spin offs and initiatives? What have they delivered? What are they promising to deliver? Are such initiatives solutions, or partial solutions?  What do they have planned on the horizon?

• Overview of alternatives (Munos)
• PDP experience (Don)
• Current Initiatives in TB Drug Discovery/Development (Olliaro)
• MSF Access Campaign experience + regimen focus (Balasegaram)
• The view from Janssen Labs, a Johnson & Johnson company (Richter)
• The view from NIH (McKew)
• Kaggle, gamification, and other crowdfunding experiments (Bentzien)
• The view from the European Lead Factory (Tzalis)
• Spur your imagination – Examples from other fields (Menon/Neiss)

3:45 pm          Philosophy:  What Does 'Open Source' Mean?            
                          John Wilbanks, Matthew Todd              

• Definitions and minimum criteria for what counts as OS, and opportunities at each stage of the pipeline (Wilbanks)
• A Proposed distinction between open source and open innovation (Todd)

 
5:00 pm          Practice:  What is Happening in Open Source Pharma?
                         Samir Brahmachari, Matthew Todd, Tomasz Sablinski, Jaleel, UC Jaleel, Urmi Bajpai

• OSDD experience (Brahmachari)
• Open Source Malaria experience (Todd)
• Open innovation in late stages of the pipeline (Sablinski)
• The art of structuring massive collaborations (Jaleel)
• Crowdsourcing in wet labs and with undergraduates (Bajpai)
• Limitations of open source pharma (Todd)

7:00 pm         Cocktails and dinner



DAY TWO / OPEN SOURCE PHARMA: POSSIBILITIES

9:00 am          Industry Roundtable
                         Panel: Melinda Richter, Jörg Bentzien, Dimitrios Tzalis, Bernard Munos; Moderator: Z. Thomas

• What does pharma, big and small, need to become involved in neglected/non-lucrative diseases?
• What policy reforms might be valuable?
• What business model tweaks/innovations might work?

                Barriers: Public and academia

9:45 am        Group Determination – Issues Posed to the Group                     

• What are the big questions that need further discussion?

• Joint planning/The un-conference: How do we want to spend our remaining time together?

11:00              Collaborative Session

• Two short videos
• 'Vision of the future' exercise

11:30 am        Incentives (Plenary brainstorm)

• Who are the most relevant (existing and new) players?
• What sorts of incentives would they respond to?

12:00 pm        Option A: Open, Unstructured Conversation Among the Entire Group

                         Option B: New Energies and Resources (Small group brainstorm; 4 groups; 1 issue per group)

I. How can we enlist new players and resources to the cause?

     Group A: Innovative Finance/New Sources of Funding

• Crowdfunding (for student fellowships?)
• Tobin Tax?
• TOMS Shoes - Buy one-give one (BOGO) model
• HNIs (High net worth individuals)
• Linux/IT-oriented parties

     Group B: Human Resources

• Students
• Celeb champions
• Volunteer scientists
• Women scientists

     Group C: Citizens / Activists / Movements

• Activists
• Religious/Ethnic groups
• Doha-round types

     Group D: In-kind Resources/Innovative Partnerships

• Lab space
• IT resources
• Assays
• Pro bono scientists from pharma
• A pro bono requirement, akin to law firms, from PhRMA
• Pharma itself, as it is starting to explore open source for Alzheimers, cancer, etc.

II. All: What, generally, is your big idea to change the whole game?

III. Plenary: Vote for the best idea. Prizes for best idea in each category and for volunteers to take them forward.


1:00 pm          Lunch

2:00 pm          Start to Finish: Exploring an End-to-End System

• What does a system that actually solves a problem look like? Can we create the world's first open source (-enabled) drug?
• Interactive crowdsourcing exercise: Mapping out a) existing core players, b) new players/partners, c) opportunities for open (source) innovation, d) incentives, and e) enabling mechanisms. All at each stage of the value chain.
• In parallel: Wish list - what relatively small-but-high impact thing does your organization really need? (optional)

3:45 pm          Boat ride/free time



DAY  THREE / OPERATIONALIZING 

9:00 am         The Path Forward: Collaborative Sessions continue

• Group Brainstorming
• Partnership Cafes
• Explore/Design a Global Incentive Prize   
• Explore Creating a Global Online Platform
• Explore Creating a Global Light Touch Consortium
• Innovative pooling of IP
• Combine Ideas into a Single Proposal (e.g., MSF P proposal)
• Draft Joint Project/Funding Proposal 
• Plan Joint Academic Paper

7:00 pm          Cocktails and dinner

Back